The company, whose investors include M&G, Gartmore, Aviva, Schroders and Blackrock, as well as many private shareholders, received a big boost from the deal with Novartis. The Swiss pharmaceuticals giant will sell Sativex in Australia, New Zealand, Asia (excluding China and Japan), the Middle East and Africa.
GW already has licensing agreements with Bayer for the UK and Canada (where Sativex has been on the market since 2005), Almirall for most of Europe and Otsuka for the US. It anticipates regulatory approval later this year in Germany, Italy, Sweden, Denmark, Austria and the Czech Republic.
Yhteistyötäkin on siis jo useiden suurten lääkeyhtiöiden kanssa, ja lääkkeelle odotetaan vielä tänä vuonna hyväksyntää mm. Ruotsissa ja Tanskassa. Suomea listalle odotellessa...
0 kommenttia
Lähetä kommentti